Technology

The Oral Platform changing the Vaccination Landscape

Injectable vaccines only allow for a single line of defense. They allow for IgG- blood serum as the only Antibodies for immunity and not the IgA – Mucosal. The Oral Delivery method, on the other hand, allows for two lines of defense, by delivering both the IgA – Mucosal and the IgG- blood serum antibodies, offering greater protection from the disease.

Kinder vaccinations for Respiratory & Enteric Infectious Diseases:

QYNDR has developed an innovative, patented oral mucosal delivery platform that supports multiple applications:

Development of multiple products based on novel oral platform technologies targeting specific immune cells to provide the most robust immune response for a given disease
Broad portfolio of Oral Vaccines (Flu, Covid, Group A Strep)
Demonstrated Clinical Proof of Concept for COVID-19 vaccine demonstrated robust and long-lasting protection in First-in-Humans Clinical Trial (2021-2022)

What We Know Now

Vaccinating large populations around the world has proven to be more challenging than expected, despite significant efforts to increase the effectiveness and scale of dispensing vaccines. Major challenges remain with current vaccine technologies and manufacturing supply-chains. Vaccine distribution systems remain inadequate, especially if they require Cold Chain systems, which are expensive to scale, making them unavailable for many populations. Other issues such as requiring healthcare clinics and trained professionals, patent aversion to injections, and lack of trust in the safety, quality, and efficacy of vaccines leave many individuals unvaccinated. Such unvaccinated populations only end up serving as reservoirs for the virus, extending the risk to epidemic reemergence and undermining vaccination efforts.

Currently, approved injectable vaccines have demonstrated significant reduction in infection rates for up to six to eight months after vaccination. However, it is not yet clear what the minimum level of antibodies (IgA/IgG) is required for protection. As witnessed with the Covid-19 pandemic, booster shots or annual vaccinations will be necessary. Implementing vaccine programs on a global scale requires significant funding, complex logistics, and the cooperation of both governments and the private sector. Additionally, some individuals who have received serum-based vaccines may still carry and shed the virus through nasal secretions, making mucosal immunity (via IgA) an important factor in protecting against respiratory viruses.”

The QYNDR oral vaccine presents a solution to many of the challenges faced in scaling vaccination efforts to large populations globally. As an oral vaccine, QYNDR is easy to self-administer and can be stored at stable temperatures (5 to 35 degrees Celsius).

It can be produced under conditions similar to food production, making it more accessible and easier to distribute. Additionally, QYNDR stimulates the production of both IgA and IgG antibodies, which can help reduce the spread and incidence of infection. QYNDR can be distributed and dispensed without expensive Cold-Chain distribution systems, healthcare clinics, or trained professionals.

The QYNDR oral vaccine can be simply mailed to patients on a periodic basis and can also be used as a booster in combination with other previously approved vaccines, allowing governments and organizations to maintain a strong, vaccinated population.

All the above accomplishments confer a clear competitive advantage.

The ORAL platform technology is VERY POWERFUL as it enables targeting of a wide range of infectious diseases. It also offers increased stability if applied to existing serum-based formulations. The technology is not limited to human disease or only antiviral.

Oral Platform: Uniquely Versatile

The QYNDR method employs a unique formulation for vaccine delivery particles, which attaches antigen to gut-associated lymphoid tissue (GALT). To safeguard vaccine particles from degradation in the stomach, we use micro-encapsulated enteric coating. This combination has demonstrated an appropriate immune response in Human Trial.